Navigation Links
Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product

SIOUX FALLS, S.D., May 1, 2012 /PRNewswire/ -- pharmaCline's Diabecline® antibiotic ointment (SSPT® Tetracycline) received the Bronze Award for 2012 Best New Pharmaceutical Product at the 25th Annual Edison Awards in New York City.  pharmaCline joined some of the world's most well known corporations at the New York Academy of Sciences, which hosted the Edison Awards Innovation Showcase and Forum.  The subsequent Awards Gala event acknowledged the hard work, innovation and commitment of all of the 2012 Edison Award winners. 


"As the pace of innovation quickens and the 'race to next' becomes ever more competitive, it's increasingly important to take a moment out of our hectic lives to recognize excellence in innovation and greatness in the teams of innovators who make our future. We are honored to present pharmaCline, and its Diabecline antibiotic ointment, with an Edison Award as one of the leading innovators of today and tomorrow," says Thomas Stat, 2012 Edison Awards Steering Committee Chairman.

The Edison Award is one of the highest accolades a company can receive in the name of innovation and business.  Edison's inventions, new product development methods and innovative achievements garnered 1,093 U.S. patents and made him a household name around the world. 

"Thomas Edison is an American hero who has shaped our modern era," said pharmaCline CEO Steve Keough.  "We are honored and humbled to receive this Award."

Diabecline antibiotic ointment utilizes pharmaCline's innovative Site Specific Penetration Technology™ (SSPT Tetracycline) to provide a solution to antibiotic resistance. Antibiotic resistance is a world-wide medical emergency recognized by the World Health Organization as a serious threat to the effectiveness of modern medicine.

Dr. Margaret Chan, Director General of the World Health Organization, said, "At a time of multiple calamities in the world, we cannot allow the loss of essential antimicrobials, essential cures for many millions of people, to become the next global crisis."

pharmaCline's SVP for Sales and Marketing, Sam Michini, said, "Our innovation was to go back in history and find the most widely tolerated antibiotic that kills a broad spectrum of bacteria, and to develop a safe and effective ointment delivery system that allows penetration through the pathogen's cell walls."

This efficient delivery of the drug to the nucleus of the bacteria results in exceptional kill capabilities against the most prevalent bacterial pathogens.  The ointment also has moisture reducing properties that further prevent the development of resistance.

Thomas Edison is credited with going beyond technology and finding solutions to problems.  pharmaCline is committed to finding solutions to difficult problems, such as antibiotic resistance.  pharmaCline believes that many "old and proven solutions" can be retooled for re-use. 

"By pairing innovative technologies with other proven products, or creating our own products, we move beyond theory to solution," said Michini. "This requires intentional development tied to the real challenges in our world."

About pharmaCline
pharmaCline® is an innovative technology and pharmaceutical company that has developed a proprietary drug delivery technology called Site Specific Penetration Technology™.  Using this technology, pharmaCline has created a game-changing product line of topical hypoallergenic antimicrobial drugs.  pharmaCline's new products provide an effective solution to the antibiotic resistance crisis worldwide.

About the Edison Awards
The Edison Awards are among the most prestigious accolades honoring excellence in new product and service development, marketing, human-centered design and innovation.  Unique to the world of award programs, the Edison Awards are focused on the innovators as much as the innovations.  Award winners represent "game changing" products, services and excellence in the leadership of innovation around four criteria: concept, value, delivery and impact.

Contact Information:
Lana McCoy, Executive Marketing Coordinator
Phone: 605-271-2086
2329 N. Career Avenue, Suite 243
Sioux Falls, SD 57107

SOURCE pharmaCline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Product Profiles: Pipeline Antibacterials - Gram-Negative Combination Antibiotics Show Promise in MRSA-Focused Pipeline
2. IDSA Proposes New Pathway For Antibiotic Approval
3. AVMA Responds to Federal Order Limiting Use of Antibiotics In Food Animals
4. FDA Consumer Health Information - Video: Get Smart About Antibiotics
5. FDA Denies Citizen Petitions on Animal Antibiotics
6. Pew Supports Antibiotics Innovation Bill in Senate
7. Antibiotics Conference Addresses Lack of New Drugs to Fight Deadly Superbugs
8. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
9. Reportlinker Adds Antibiotic Manufacturers - Top 150 Antibiotic Manufacturers (Global)
10. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):